Galectin Therapeutics/$GALT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
- Ticker
- $GALT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 9
- Headquarters
- Norcross, United States
- Website
- galectintherapeutics.com
GALT Metrics
BasicAdvanced
$350M
-
-$0.43
0.39
-
Price and volume
Market cap
$350M
Beta
0.39
52-week high
$7.13
52-week low
$2.03
Average daily volume
198K
Financial strength
Current ratio
0.097
Quick ratio
0.088
Long term debt to equity
-0
Total debt to equity
-1.052
Interest coverage (TTM)
-2.02%
Profitability
Management effectiveness
Return on assets (TTM)
-64.18%
Return on equity (TTM)
21.92%
Valuation
Price to book
-1.65
Price to tangible book (TTM)
-1.65
Price to free cash flow (TTM)
-14.229
Free cash flow yield (TTM)
-7.03%
Free cash flow per share (TTM)
-0.244
Growth
Earnings per share change (TTM)
-33.10%
3-year earnings per share growth (CAGR)
-13.93%
10-year earnings per share growth (CAGR)
-7.01%
What the Analysts think about GALT
Analyst ratings (Buy, Hold, Sell) for Galectin Therapeutics stock.
Analyst projections of the future price of Galectin Therapeutics stock.
Bulls say / Bears say
NAVIGATE showed a useful efficacy signal: new varices were numerically lower with 2 mg belapectin in the full analysis, and significantly lower in the per-protocol group. Fibrosis markers and the drug’s safety profile also supported further testing. (Galectin Therapeutics)
Galectin says it reached agreement with the FDA on key Phase 3 design elements, including the primary endpoint and central review process. This gives belapectin a clearer route towards a registrational trial and potential full approval. (GlobeNewswire)
The chairman converted about $105.8 million of debt into equity, removing a large debt burden and strengthening Galectin’s balance sheet as it advances belapectin. (U.S. Securities and Exchange Commission)
NAVIGATE did not meet its composite primary endpoint in the full study population. The stronger varices result was confined to the per-protocol analysis, leaving efficacy uncertain ahead of Phase 3. (Investing.com)
Galectin had $13.3 million in cash at the end of June and said this, with available credit, would fund planned operations only through June 2027. Its filing also warned of substantial doubt about its ability to continue without raising more capital. (U.S. Securities and Exchange Commission)
The debt conversion required issuing 34.4 million shares to the chairman, diluting existing shareholders. Galectin also identifies its dependence on the chairman for financing as a risk, concentrating financial influence in one investor. (U.S. Securities and Exchange Commission, U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.
GALT Financial Performance
Revenues and expenses
GALT Earnings Performance
Company profitability
Upcoming events
No upcoming events
GALT News
AllArticlesVideos
Funds containing GALT
Fund name | Fund size | $GALT weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.00% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.